Literature DB >> 22234982

The window hypothesis: haemodynamic and non-haemodynamic effects of β-blockers improve survival of patients with cirrhosis during a window in the disease.

Aleksander Krag1, Reiner Wiest, Agustín Albillos, Lise Lotte Gluud.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22234982     DOI： 10.1136/gutjnl-2011-301348

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  43 in total

Review 1.  Bacterial infections in end-stage liver disease: current challenges and future directions.

Authors:  Jasmohan S Bajaj; Jacqueline G O'Leary; Florence Wong; K Rajender Reddy; Patrick S Kamath
Journal:  Gut       Date:  2012-06-03       Impact factor: 23.059

Review 2.  Treatment and management of ascites and hepatorenal syndrome: an update.

Authors:  Kurt Lenz; Robert Buder; Lisbeth Kapun; Martin Voglmayr
Journal:  Therap Adv Gastroenterol       Date:  2015-03       Impact factor: 4.409

Review 3.  [Renal insufficiency in patients with hepatic insufficiency].

Authors:  K Lenz; M Binder; R Buder; A Gruber; B Gutschreiter; M Voglmayr
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-26       Impact factor: 0.840

Review 4.  Portal vein thrombosis in cirrhosis: Controversies and latest developments.

Authors:  Damian J Harding; M Thamara P R Perera; Frederick Chen; Simon Olliff; Dhiraj Tripathi
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

5.  Use of non-selective beta blockers in cirrhosis: the evidence we need before closing (or not) the window.

Authors:  Vincenzo La Mura; Giulia Tosetti; Massimo Primignani; Francesco Salerno
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

6.  Thromboelastometry in patients with advanced chronic liver disease: a complex interplay.

Authors:  Sanchit Sharma
Journal:  Hepatol Int       Date:  2021-01-29       Impact factor: 6.047

7.  Hemodynamic Response to Carvedilol is Maintained for Long Periods and Leads to Better Clinical Outcome in Cirrhosis: A Prospective Study.

Authors:  Vijendra Kirnake; Anil Arora; Varun Gupta; Praveen Sharma; Vikas Singla; Naresh Bansal; Mohan Goyal; Romesh Chawlani; Ashish Kumar
Journal:  J Clin Exp Hepatol       Date:  2016-01-23

Review 8.  Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension.

Authors:  Alberto Ferrarese; Alberto Zanetto; Giacomo Germani; Patrizia Burra; Marco Senzolo
Journal:  World J Hepatol       Date:  2016-08-28

Review 9.  Nonselective Beta-Blockers Do Not Affect Survival in Cirrhotic Patients with Ascites.

Authors:  Antonio Facciorusso; Sunil Roy; Sarantis Livadas; Adwalia Fevrier-Paul; Clara Wekesa; Ismail Dogu Kilic; Amit Kumar Chaurasia; Mina Sadeq; Nicola Muscatiello
Journal:  Dig Dis Sci       Date:  2018-05-03       Impact factor: 3.199

10.  Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers.

Authors:  Richa Shukla; Jennifer Kramer; Yumei Cao; Jun Ying; Aylin Tansel; Annette Walder; Shailesh Advani; Hashem B El-Serag; Fasiha Kanwal
Journal:  Am J Gastroenterol       Date:  2016-09-27       Impact factor: 10.864
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.